CD38 and Miyoshi myopathy: The MM cohort treated with anti-CD38 (G3a, 9 of 17 responders, Figure 1D) showed greatly impacted ACE2 binding inhibition (~50% response rate) while the cohorts of WM on-therapy (G1, 1 of 10 responders, Figure 1B) and MM treated with anti-BCMA (G3b, 1 of 3 responders, Figure 1E) showed the lowest responses (~10–30% response rate).